JUNSHI BIO Seeks Shareholders’ Nod for 10% H-Share Buyback Mandate

Shanghai Junshi Biosciences Co., Ltd. (JUNSHI BIO) has issued a circular dated 8 July 2026 convening a First Extraordinary General Meeting (EGM) on 27 July 2026 in Shanghai. The sole special resolution seeks authority for the Board to repurchase up to 10% of the company’s issued H shares on the Hong Kong Stock Exchange.

Key terms of the proposed mandate • Scope: Repurchase of up to 26.03 million H shares, equivalent to 10% of the 260.30 million H shares outstanding (total share capital: 1.03 billion shares, comprising 766.39 million A shares and 260.30 million H shares). • Price ceiling: Not higher than 105% of the average closing price of the five trading days preceding each buyback. • Validity period: From approval at the EGM until the earlier of (1) the conclusion of the next annual general meeting or (2) revocation/variation by shareholders. • Share handling: Repurchased shares may be cancelled, held as treasury shares, or otherwise dealt with in accordance with prevailing regulations.

Funding and capital impact The buybacks will be financed solely from internal resources allowed under PRC law, the Hong Kong Listing Rules, and the company’s Articles of Association. Directors state that a full-scale exercise of the mandate would not materially impair working capital or the group’s gearing position.

Rationale The Board views the mandate as a tool to protect shareholder interests and provide flexibility to repurchase shares when market conditions are favourable, aiming to enhance net asset value per share and earnings per share.

Share-price context Over the 12 months to July 2026, JUNSHI BIO’s H share price traded between a high of HKD 38.64 (September 2025) and a low of HKD 15.25 (June 2026).

Governance and timetable • Record date: 27 July 2026; H-share register closed 22–27 July 2026 (both days inclusive). • Proxy forms for H-shareholders must be lodged with Tricor Investor Services by 2:50 p.m. on 26 July 2026. • Voting at the EGM will be conducted by poll.

No share repurchases have been executed in the six months preceding the circular. Directors and core connected persons have indicated no current intention to sell shares to the company under the proposed mandate.